Camurus AB (publ) (CAMX.ST)
SEK 574.5
(1.77%)
SEK 574.5
(1.77%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 24.5 Million SEK | -6.52% |
| 2022 | 26.21 Million SEK | 2.19% |
| 2021 | 25.65 Million SEK | 0.69% |
| 2020 | 25.48 Million SEK | -6.77% |
| 2019 | 27.33 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 22.81 Million SEK | -6.91% |
| 2024 Q2 | 20.95 Million SEK | -8.15% |
| 2023 Q3 | 25.29 Million SEK | -5.54% |
| 2023 FY | 24.5 Million SEK | -6.52% |
| 2023 Q1 | 24 Million SEK | -8.44% |
| 2023 Q4 | 24.5 Million SEK | -3.1% |
| 2023 Q2 | 26.77 Million SEK | 11.54% |
| 2022 Q1 | 23.98 Million SEK | -6.5% |
| 2022 FY | 26.21 Million SEK | 2.19% |
| 2022 Q4 | 26.21 Million SEK | 4.32% |
| 2022 Q3 | 25.13 Million SEK | 12.7% |
| 2022 Q2 | 22.3 Million SEK | -7.04% |
| 2021 Q4 | 25.65 Million SEK | -2.99% |
| 2021 Q1 | 24.21 Million SEK | -4.96% |
| 2021 Q2 | 22.93 Million SEK | -5.28% |
| 2021 Q3 | 26.44 Million SEK | 15.31% |
| 2021 FY | 25.65 Million SEK | 0.69% |
| 2020 FY | 25.48 Million SEK | -6.77% |
| 2020 Q2 | 25.14 Million SEK | -4.22% |
| 2020 Q3 | 23.74 Million SEK | -5.57% |
| 2020 Q4 | 25.48 Million SEK | 7.3% |
| 2020 Q1 | 26.25 Million SEK | -3.94% |
| 2019 FY | 27.33 Million SEK | 0.0% |
| 2019 Q4 | 27.33 Million SEK | 4.27% |
| 2019 Q3 | 26.21 Million SEK | -3.04% |
| 2019 Q2 | 27.03 Million SEK | -2.95% |
| 2019 Q1 | 27.85 Million SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | -52.246% |
| Ziccum AB (publ) | 857 Thousand SEK | -2759.627% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -392.207% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | -0.078% |
| Genovis AB (publ.) | 79.32 Million SEK | 69.104% |
| Intervacc AB (publ) | 181 Thousand SEK | -13439.779% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | -18.903% |
| Active Biotech AB (publ) | 3 Million SEK | -716.9% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | 59.36% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -390.14% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | 65.681% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | -213.068% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -5679.953% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 77.434% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -698.274% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -849.884% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -2350.7% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 97.497% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | 11.097% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 97.173% |
| Cyxone AB (publ) | 858 Thousand SEK | -2756.294% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -1332.32% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | 33.419% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -3579.73% |
| SynAct Pharma AB | 637 Thousand SEK | -3747.253% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -2783.176% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -1291.652% |
| BioInvent International AB (publ) | 23.24 Million SEK | -5.434% |
| Alzinova AB (publ) | 800 Thousand SEK | -2963.375% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 76.986% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -3070.047% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | 72.992% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | 20.1% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 89.413% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -2209.802% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |